Publicaciones en colaboración con investigadores/as de University of Groningen (18)

2024

  1. Effect of Avenciguat on Albuminuria in Patients with CKD Two Randomized Placebo-Controlled Trials

    Journal of the American Society of Nephrology, Vol. 35, Núm. 9, pp. 1227-1239

  2. Effects of Zibotentan Alone and in Combination with Dapagliflozin on Fluid Retention in Patients with CKD

    Journal of the American Society of Nephrology, Vol. 35, Núm. 10, pp. 1381-1390

  3. Glomerular and tubular effects of dapagliflozin, eplerenone and their combination in patients with chronic kidney disease: A post-hoc analysis of the ROTATE-3 study

    Diabetes, Obesity and Metabolism, Vol. 26, Núm. 2, pp. 576-582

2023

  1. Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial

    American Journal of Kidney Diseases, Vol. 82, Núm. 1, pp. 84-96.e1

2022

  1. A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function

    Kidney International, Vol. 101, Núm. 1, pp. 174-184

  2. Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and their Combination in Patients with Chronic Kidney Disease: A Randomized Cross-over Clinical Trial

    Journal of the American Society of Nephrology, Vol. 33, Núm. 8, pp. 1569-1580

  3. Bending oxygen saturation index and risk of worsening heart failure events in chronic heart failure

    European Journal of Heart Failure, Vol. 24, Núm. 11, pp. 2108-2117

2021

  1. Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial

    Circulation, Vol. 143, Núm. 18, pp. 1735-1749

  2. Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: The CREDENCE trial

    European Heart Journal, Vol. 42, Núm. 48, pp. 4891-4901

  3. Effects of dapagliflozin in stage 4 chronic kidney disease

    Journal of the American Society of Nephrology, Vol. 32, Núm. 9, pp. 2352-2361

  4. Effects of dapagliflozin on mortality in patients with chronic kidney disease: A pre-specified analysis from the DAPA-CKD randomized controlled trial

    European Heart Journal, Vol. 42, Núm. 13, pp. 1216-1227

  5. Large between-patient variability in egfr decline before clinical trial enrollment and impact on atrasentan’s efficacy: a post hoc analysis from the SONAR trial

    Journal of the American Society of Nephrology, Vol. 32, Núm. 11, pp. 2731-2734

2020

  1. CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction

    American Journal of Medicine, Vol. 133, Núm. 3, pp. 370-380.e4

  2. Rationale and protocol of the Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial

    Nephrology Dialysis Transplantation, Vol. 35, Núm. 2, pp. 274-282

  3. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 35, Núm. 10, pp. 1700-1711

2018

  1. European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care: European ADPKD Forum and Multispecialist Roundtable participants

    Nephrology Dialysis Transplantation, Vol. 33, Núm. 4, pp. 563-573

2016

  1. International Multi-Specialty Delphi Survey: Identification of Diagnostic Criteria for Hepatic and Renal Cyst Infection

    Nephron, Vol. 134, Núm. 4, pp. 205-214

2013

  1. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease

    New England Journal of Medicine, Vol. 369, Núm. 26, pp. 2492-2503